MIT Study Reveals Novel Lung Cancer Drug Resistance Pathways

Researchers at MIT have identified two distinct mechanisms by which lung tumor cells develop resistance to KRAS inhibitors, a class of drugs used in cancer treatment. Beyond the previously understood reactivation of KRAS activity, the study revealed that some lung tumors can undergo a transformation from adenocarcinoma to squamous cell carcinoma. This discovery offers critical new insights into drug resistance, potentially guiding future treatment strategies for lung cancer patients.